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NEWS AND VIEWS
Harnessing the Human Genome Through
Legislative Constraint
GEORGE P. SMITH, II
Professor of Law, The Catholic University of America,
Washington, D.C, 20064, USA
Abstract:
The awesome predictive power of genetic medicine promises great advancements in not only
the treatment of identifiable conditions but the prevention of their pathological manifestations.
At the same time, the release and dissemination of this genetic or medical information poses a
distinct risk of loss of privacy and stigmatization to carriers of genetic disorders. In order to
safeguard the individual right of autonomy, privacy, confidentiality and informed consent-yet
accommodate the legitimate interests of employers and insurers to obtain medical information
relevant to their professional needs and economic responsibilities a balance must be struck
legislatively at the federal and state levels of government.
Key words:
American legislative efforts to prevent genetic discrimination.
1. Introduction
In 1973, Theodosius Dobzhansky warned that there was no better way to
attack the goal and the standard of social equality than to demonstrate that
since people are innately genetic they are therefore irremediably diverse and
unlike. Human equality, however, should be recognized and tied not to bodily
or even mental characteristics but, rather, to an appreciation and acceptance
of the fact that it is more correctly to be found, achieved and honoured
through protection of those fundamental rights which arise from the very
sacredness of life, itself, and are realized within every human being.
2
While abundant fears mark the pathways for the development of the New
Biology, humanity's dehumanization and depersonalization will not be
fostered-in reality-as a consequence of the continuing quest for mastery of
the genetic code through pursuit of the Human Genome Initiative. Indeed, if
actions are undertaken and performed here with the goal of minimizing
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human suffering and maximizing the social good, then the noble integrity of
evolutionary and genetic progress will be preserved and the "slippery slope"
of careless and irrational action will be avoided totally
Obviously, attendant to the freedom to undertake research into the exciting
frontiers of the New Biology is a co-existent responsibility to pursue the work
in a reasonable and rational manner. The real-although often exaggerated-
threats to genetic privacy, and the resulting forms of genetic discrimination,
posed as a consequence of research in this field, can be contained by careful
development and application of legal norms through legislative schemes at the
state and federal levels of government. In partnership, law and science should
seek to develop a contemporary agenda for social change that also seeks to
fulfil socio-political goals.
When viewed as but a tool for enhancing the health of the nation's citizens,
and of engineering humanity's genetic weaknesses out of the line of
inheritance, biological determinism is an absolute necessity for trans-national
survival in the 21st century, Simply stated, healthier and genetically sound
individuals have a much better opportunity for pursuing and achieving the
"good life" and making a significant contribution to society's greater well-
being or, in other words, social good.
2. Insurance Discrimination
Once genetic testing is offered widely and accurately, it may become quite
useful to at-risk individuals if they are enabled thereby to pursue measures
designed to reduce their vulnerability to those diseases to which they have
been predisposed genetically. Yet, in the crucial interim before widespread
testing and successful treatment or cures occur, the acquisition and release of
genetic information poses a threat especially to those employed in the work
force-namely, a loss of jobs, health insurance and privacy. Prohibiting
discrimination based on genetic testing information hence becomes an issue
of civil rights and the preservation thereof'
The essential dilemma seen here is actually a hydra-headed one. Thus, if
it is known that certain individuals have a predisposition to develop certain
genetic diseases over time, they-themselves-will be motivated, most
assuredly, to obtain insurance coverage at bargain premiums long before their
conditions become manifest seeking thereby to transfer their anticipated
financial losses to others. If insurance companies do not have access to this
testing information, the very viability of the insurance industry is threatened.
Contrariwise, if genetic test information is revealed to insurance
companies, it is likely that the information would be used to discriminate in
NEWS AND VIEWS
underwriting by charging not only higher premiums, but excluding coverage
of genetically caused conditions oi-for that natter-refusing to offer any
coverage at all to the genetically unlucky individuals. To be remembered is
the fact that genetic testing is rarely determinative of whether a specific
individual will suffer from a disease. Even if determinative tests are achieved,
they will be unable to reveal either the severity or time of onset of the actual
disease. If, ultimately, loss of all insurance coverage results from disclosures
of genetic information, the government will be forced to regulate directly the
insurance industry and/or offer governmental insurance for genetically at-risk
individuals.
2.1 Genetic Testing Groups and Genetic Information
Genetic tests, in a broad sense, provide information regarding three types of
individuals: those who are presently asymptomatic and will probably acquire
a range of disabilities from adult-onset conditions (e.g., Huntington's chorea,
amyotrophic lateral sclerosis, adult polycystic kidney disease); those who,
while currently asymptomatic, carry a genetic predisposition, which-while
not certain-may lead to the development of heart disease, diabetes, and
colon cancer, for example; and-finally-those people who, while carrying
the genes for conditions such as hemophilia, sickle cell anemia, or Tay-Sachs
will never themselves have the diseases but may pass them to their children.
Genetic information, then, can be seen as but one type of medical
information-for it is collected in much the same way and, indeed, used for
the very same purposes as other such information obtain in medical
examinations.
There are legitimate, nondiscriminatory reasons for employers to obtain
complete medical (including genetic) information about their current and
prospective work force. Many jobs require employees to have demonstrable
physiologic, sensory and neurologic abilities. Just as educational pre-
requisites and skill requirements can be assessed and evaluated, it is by use of
a medical examination that physiological limits and predispositions can be
determined.' When it is realized that health coverage for nearly two-thirds of
all who have any kind of health insurance is provided by employers, the
magnitude of the economic investment here is simply staggering. Added to
this is also valid managerial concern about future risks of potential employee
pay-outs in health benefits as future incapacities are factored into the
demands of contemporary job profiles.'
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2.2 Screening Guidelines
Three working principles should be implemented by employers as they
develop genetic screening programs in the workplace. First, there should be
an understanding even before a screening program is operational that, all
ethical issues central to its success must be explored. Second, before any
screening is conducted, the individual employees in the program should give
their informed consent for participation. Finally, not only should counselling
be offered before and after screening occurs, but resources must be set aside
for any reasonable intervention which could provide a positive benefit to theindividuals who are screened before the actual screening is undertaken.
2.3 The United States Position
In the United States, under current law, employers are not compelled to limit
either medical inquiries or examinations to the physical requirements of
specific jobs. 1° The implementing regulations of The Americans with
Disabilities Act do require that genetic information obtained be not only kept
confidential but maintained separately from all other employee personnel
records. l
Although permitted to collet whatever information thought necessary at
the post-offer stage, physicians are supposed to limit their communications to
the personnel office solely to that information bearing directly upon the
applicant-employee ability to perform enumerated tasks." Yet, employers may
nonetheless seek to obtain medical information relevant to an applicant-
employees presymptomatic status, genetically caused sensitivity to workplace
carcinogens or genetic predisposition to disease-all with the purpose of
denying work to applicants or laying off or even discharging present
employees whose medical problems are discovered. As more employers
become self-insured, even with legislated restrictions imposed upon the
release of genetic information, it becomes relatively easy for employers to still
learn about the health of their workers and that of their families, by simply
reviewing health insurance claims.
Forced disclosure of diagnostic studies to others, against a patient's will,
would be recognized as appropriate in those situations where there is either a
high probability of harm or where serious harm to identifiable individuals will
occur most probably or in those cases where full precautions are followed
which seek to limit the ultimate disclosure of only that 4enetic information
considered appropriate to the needs of the particular case.
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3. Seeking a Federal and State Legislative Solution
3.1 The Human Genome Privacy Act
In the area of privacy, there have been several legislative proposals which
merit study. The Human Genome Privacy Act (HGPA) was introduced before
the House of Representatives by Representative John Conyers on September
13, 1990. Although no action was taken on the bill following its introduction,
its language responds in many aspects to the problems of confidentiality of
genetic information in the workplace. It may be fully expected that similar
legislation will be proposed over time. The purpose of the bill was "to
safeguard individual privacy of genetic information from the misuse of
records maintained by agencies or their contractors or grantees for the
purpose of research, diagnosis, treatment, or identification of genetic
disorders" The bill would have provided individuals access to records
concerning their genome as maintained for any purpose by agencies of the
federal government. The language of this proposed legislation may be
studied as a potential model for future legislation both at the federal and state
levels. 20
From a policy perspective, the HGPA would overlap with two important
federal statutes. In lieu of enacting new legislation, Congress could easily
amend either the Americans with Disabilities Act (ADA) or the Privacy Act
in order to include relevant provisions of the HGPA. Although addressing
analogous discrimination and privacy issues, the ADA and the Privacy Act fall
short of extending explicit protection to asymptomatic individuals with
abnormal genotypes.
Regarding disabilities under the ADA, the current policy is "can't ask,
don't tell." The major uncertainty with this policy is "whether a genetic trait
that has not manifested itself counts as a disability within the meaning of the
statute."
It would appear that the most fruitful path in the legislative arena would be
by amendment to these legislative schemes. As amended, these statutes should
recognize the fundamental importance of privacy and equality rights while
explicitly extending the protection of these principles to problems of
discrimination based on disclosure and dissemination of genomic
information. Such amendments to an established statutory framework would
simplify the process of effectuating newly enacted protections, rather than
establishing a new area of law subject, in turn, to the promulgation of complex
regulations and interpretative judicial clarification.
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3.2 The Genetic Privacy Act and Its Permutations
The Genetic Privacy Act was drafted, initially, in 1995 by Professors George
J. Annas and Leonard H. Glantz, together with Patricia Roche, of the Health
Law Department of the Boston University School of Public Health. A grant
from the United States Department of Energy supported this project. A
version of this Act entitled, "The Genetic Privacy and Nondiscrimination Act
of 1995" was submitted subsequently to the Congress by the then Senator
Mark 0. Hatfield of Oregon whereupon it was referred to the Senate Law and
Human Resources Committee.25 Representative Clifford B. Sterns of Florida
introduced the same bill in the House of Representatives where, in turn, it was
referred to the House Committees on Commerce, Economic and Educational26
Opportunities and Government Oversight. Both of these legislative
proposals died in committee.
When legislative proposals "die" in committee, they do so because the
chairman of the particular committee to which a bill is assigned, for whatever
reasons, chooses not to place the proposed legislation on the committee
agenda for a hearing on its merits. When such an action occurs, a bill is
stopped effectively for that particular session of the Congress. Alternatively,
a recommendation may come from a committee to the full house (or senate),
that proposed legislation be "killed" formally or postponed indefinitely and
thus not 'considered. A house vote confirming a committee report or
recommendation of this nature has the effect of also officially killing a bill.2'
The Annas-Glantz-Roche proposed legislation aims to place legal
safeguards on the collection, analysis and storage of DNA and genetic
information. It is from analysis and storage of DNA samples (e.g., blood,
saliva, hair and other tissue) that genetic information is derived-for these
samples contain an individual's private genetic information. Thus, any
custodian of such samples has complete power to analyze and re-analyze them
in an effort to derive new genetic information as more advanced tests are, in
fact, developed."
The central tenet of the original Genetic Privacy Act is to forbid the
acquisition of DNA samples or genetic information about another individual
unless, "that individual specifically authorizes the collection of DNA samples
for the purpose of genetic analysis, authorizes the creation of that private
information, and has access to and control over the dissemination of that
information."3 0
3.3 Genetic Confidentiality and NonDiscrimination
On March 11, 1997, Senator Pete V Domenici of New Mexico introduced
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Senate Bill 422 entitled, "The Genetic Confidentiality and Nondiscrimination
Act of 1997" whereupon it was referred to the Labor and Human Resources
Committee. 1 Representative Sterns re-introduced his version of the Genetic
Privacy Act, entitled "The Genetic Privacy and Nondiscrimination Act of
1997:' ' 2 Both these bills follow the broad mandates of the original Genetic
Privacy Act developed by Professor Annas and his associates.
Under the Domenici draft, Section 201 mandates "a person may disclose
genetic information characterized from the DNA sample of an individual only
with the written authorization of the individual..." Individuals are,
furthermore, given the opportunity to make clear choices regarding the uses
to which the tissue they donate for research are put."
When used as part of a research project, a DNA sample may be analyzed
only, when for example, an Institutional Review Board has determined such
samples are an essential part of a research project, the potential benefit to
society of the project outweighs the risks to the research subjects, the research
protocol contains adequate safeguards to project against disclosure of genetic
information as well as requires an informed consent by the subjects who
participate in the project.
This bill also has provisions disallowing any requests or reguirements for
personal genetic information as a condition of employment or insurance
coverage, except for what may be necessary to protect employees from
hazards in the workplace. A level of legal liability for employment
discrimination based on the unauthorized disclosure of genetic information is
set at $50,000.00-with treble damages being assessed in cases where the
discrimination has resulted in profit or gain to the employer."7
3.4 Limiting the Disclosure of Genetic Information and Safeguarding
Women's Health
On March 27, 1996, H.R. 3178 was introduced by Representative Louise M.
Slaughter of New York in the United States House of Representatives entitled
the "Women's Health Equity Act of 1996." Under Title II of the proposed
legislation, Subtitle B, is found the Genetic Information Nondiscrimination in
Health Insurance Act of 1996. On April 23, 1996, the duplicate Senate version
of the proposed legislation was introduced by Senator Olympia J. Snow of
Vermont under the same title as found in Title II of the Health Equality Act."
The Genetic Information Nondiscrimination in Health Insurance Act of
1996 is designed simply to prevent an insurance provider from either
requesting or requiring "an individual to whom the provider provides health
insurance coverage, or an individual who desires the provider to provide
health insurance coverage, to disclose to the provider genetic information
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about the individual or family members of the individual." Similarly, no
denial or cancellation of health insurance coverage or a variance in premiums,
terms or conditions for health insurance coverage for an individual or a family
member of an individual is allowed under the Act.
Proceeding to define "genetic information" as information about genes,
gene products, or inherited characteristics, the Act empowers the Secretary
of Health and Human Services to promulgate necessary regulations to effect
the purpose of the proposed legislation and authorizes civil actions and/or
legal relief in monetary damages to enforce it.
Before an insurance company ever seeks to disclose any genetic
information about an individual policy holder, it must have first received prior
written authorization from that individual or from his legal representative.
Each disclosure of information must be accompanied with a specific
authorization and must "include an identification of the person to whom the
disclosure would be made.""
Having died subsequently in committee, the undaunted Representative
Slaughter introduced a similar bill on January 7, 1997, to the 105th Congress
entitled, "The Genetic Information Nondiscrimination in Health Insurance
Act of 1997."4 In her introduction of this Bill, she expressed her hope that this
proposal would enable women to take newly developed genetic tests in order
to determine their susceptibility to breast cancer and thereby,
"ensure that no American woman will have to worry that if she takes a
genetic test for BRCA or BRCA 2 breast cancer gene, she will lose her
insurance coverage; or, that if she develops breast cancer, shc will be
denied coverage for treatment because her genetic pre-disposition will be
considered a 'pre-existing condition."'46
Section Two of this 1997 proposed legislation seeks to amend the Employee
Retirement Income Security Act of 1974 to prevent group health insurance
coverage from being denied, cancelled or refused renewal or from varying the
premiums, terms or conditions on the basis of information or because a
participant or beneficiary has either requested or received genetic services. A
group health plan is forbidden from requesting or requiring either a
participant or a beneficiary to disclose genetic information about a
participant, beneficiary or applicant.
Section Three of the legislation seeks to amend the Public Health Service
Act by requiring that a group health plan or a health insurance issuer offering
health insurance coverage not disclose genetic information about a participant
or beneficiary (or applicant for coverage) without first obtaining the
authorization of anyone seeking to participate in the health plan.
Defining "genetic information" consistent with the previous definition of
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it as used in Representative Slaughter's 1996 proposed legislation on genetic47
nondiscrimination, this new 1997 Bill authorizes individual civil actions for
violations of the proposed law and allows for the assessment of compensatory,
consequential and punitive damages. On January 21, 1997, Senator Olympia
Snow co-sponsored Representative Slaughter's 1997 proposal as Senate Bill
99.
3.5 State Responses
Over the last several years, a number of states have also shown their
legislative interests in limitiny not only the accessibility to genetic
information, but its uses as well. 4Wisconsin, for example, in 1991 prohibited
health insurance from not only requiring or requesting an individual or a
member of an individual's family to obtain a genetic test and, furthermore,
requiring or requesting directly or indirectly into the results of a genetic test
but also forbade conditioning the provision of insurance coverage or benefits
on genetic testing as well as considering genetic testing results in determining
rates. This approach is considered an exceptionally balanced model-for not
only does it seek to integrate protection against
discrimination, for example, insurance practices and coverage, but also grants
a level of privacy protection for the insured and his family.
Similar approaches to the Wisconsin model have been seen in legislation52
passed successfully in thirteen states. Rather than focusing on structuring
prohibitions against discrimination based on genetic information taken from
medical records and physical examinations, these state statutes emphasize
controlling the genetic test, itself. Interestingly, task forces or commissions
to study the social and legal ramifications of the acquisition and disclosures
of genetic information have been organized in Nebraska, Ohio and Virginia.
4. Future Concerns and Potential Resolutions
Until health care is made available in the United States to all citizens
regardless of their present or future health status under national health reform,
it has been urged that a moratorium on the use of genetic information in
insurance underwriting be observed. t' Alternatively, it is suggested that only
single-gene disorders which cause a definite disease (as opposed to genetic
predisposition) should not be insured against. Yet another proposal would
utilize state created "high risk pools." Thus, while permitting the use of
genetic information by insurers in medical underwriting of individuals who
are uninsurable medically, these pools would be financed as such by a
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combination of, for example, individual premiums, payments by commercial
insurers and state revenues.
If employers continue to hold a financial stake in the American health care
system of the future, the central question to be posited is: "whether changes
in health care will simply shift the incentive to discriminate from the insurer
to the employer." To be remembered is the fact that presently "bad insurance
risks" are discriminated by life insurance companies with coverage being
either denied or provided at much higher premiums for those who either
engage in hazardous activities or whose life styles include unhealthy habits
such as smoking. Car insurance coverage premiums are also determined
based upon the age, experience, occupation and previous accident convictions
of the applicant-insured. It would require very little for insurance adjusters
to consider either long or short term genetic risks in writing a health or life
insurance policy.
5. Conclusion
Man's dehumanization and depersonalization will not be fostered as a
consequence of the continued quest for mastery of the genetic code. Attendant
to the freedom to undertake research into the exciting and fertile frontiers of
the "New Biology" is a coexistent responsibility to pursue the work in a
reasonable and rational manner. Pursuing the "New Biology" in such a
manner requires adequate attention to the safety factor in all aspects of the
experimentation. The undesirable events of a Brave New World can be
tempered only when knowledge is pursued with the purpose of establishing
the truth and integrity of the question, issue, or process. The vast potential
for advancing society and ridding it of a verisimilitude of its present ills is an
obvious good which must be pursued steadily. Little sustaining harm can
result from a reasonable pursuit of truth and knowledge; for, indeed, truth and
knowledge are the basic interstices in any balancing test. If actions are
undertaken and performed with the goal of minimizing human suffering and
maximizing the social good, then the noble integrity of evolution and genetic
progress will be preserved.
Maii must endeavour to execute his investigatory and manipulative or
creative powers within the scientific laboratory with a rational purpose and in
a spirit of humanism. Man should seek to minimize human suffering, thereby
contributing to the social goal of allowing each member of society an equal
opportunity to achieve their maximum output within the economic market
place, and to maintain personal integrity and seek spiritual tranquillity.
Genetic engineering which contributes to the social good should be utilized
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fully. There can be no real doubt that genetic manipulation provides a perilous
opportunity that may either threaten freedom or enhance it depending upon
the balance struck between its use for individual need satisfaction and societal
64good. The role of the government at both the federal and state level, must be
to ensure that this balance be struck and maintained through realistic
legislative safeguards. Some government control is needed obviously. The
level of governmental oversight must be always tempered with the reality that
as Ralph Waldo Emerson, stated, "The less government we have, the better."
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